ACTR-62. PHASE I/II STUDY OF TEMOZOLOMIDE PLUS NIMUSTINE CHEMOTHERAPY FOR RECURRENT MALIGNANT GLIOMAS: KYOTO NEURO-ONCOLOGY GROUP

The objective of this phase I/II study was to examine the efficacy and toxicity profile of temozolomide(TMZ) plus nimustine (ACNU) Patients who had received a standard radiotherapy with one or two previous chemo-regimens were enrolled. In phase I, the maximum-tolerated dose (MTD) by TMZ (150mg/m2/da...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Aoki, Tomokazu, Arakawa, Yoshiki, Ueba, Tetsuya, Oda, Masashi, Nishida, Namiko, Akiyama, Yukinori, Tukahara, Tetsuya, Iwasaki, Koichi, Mikuni, Nobuhiro, Miyamoto, Susumu
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2018
Teme:
Abstracts
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216470/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.092
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items